MIT Technology Review reports on HIV prevention shots and a broken sex doll

MIT Technology Review reports on HIV prevention shots and a broken sex doll

MIT Technology Review published this edition of The Download on March 14, 2025. It leads with lenacapavir, a drug the newsletter says prevented HIV infections in 100% of women and girls who received it in a clinical trial. The newsletter calls that trial the most successful yet seen for HIV prevention and says the drug was safe and needed injections twice a year for full protection. It also reports early results from a small phase I trial of once-yearly injections, explaining that these trials test a drug’s safety in healthy volunteers. The newsletter calls the results “incredibly promising,” while directing readers to a separate story for more detail. Whether once-yearly injections can offer protection, and how safe they are, remains unknown from the information presented here. The edition also points to Leo Herrera’s short fiction about intimate relationships with robots and what might happen when those robots break.

Publication: 9cd9e4b1-a157-d96e-51dc-d899c0152137

attribution — pass: The Download is a single newsletter edition that comments on items in its own words, so it is one piece. The reading attributes the lenacapavir claims and characterisations to MIT Technology Review's newsletter rather than stating them as fact. It also credits the fiction to Leo Herrera. Jessica Hamzelou, who wrote the lead item, is not named, but this does not misattribute anything.

This annual shot might protect against HIV infections

summary — pass: The reading states that the edition leads with lenacapavir and gives the newsletter's characterisations. It explains phase I trials in plain language, matching the source's "first in human" safety-testing description. It also notes the fiction item. Focusing on the two headline items of a roundup is a reasonable scope. The question follows from the gap between the safety-focused early trial and the hoped-for protection.

These early “first in human” trials are designed to test the safety of a drug in healthy volunteers.

date — pass: The originalPublished date of 2025-03-14 at day precision matches the URL path, and the reading states it at the same precision. The page carries later-looking Deep Dive teasers, such as 377 math findings and a 22-nation AI body; these are possible later additions. The reading neither uses nor relies on them. It uses no hindsight framing, and the twice-yearly results are reported as the newsletter's account. The evidence is a publisher page, so no archive disclosure is needed.

This week, the results of a small phase I trial for once-yearly lenacapavir injections were announced at a conference in San Francisco.

support — pass: Each claim matches an exact source excerpt. The "incredibly promising" quote and "most successful yet seen" are attributed paraphrases of the source. The reading says that whether yearly injections protect, and how safe they are, is unknown from the information here. That limitation is correctly drawn from the source's statement that the trial tests safety and its deferral to a separate story. It does not invent benefits or outcomes.

Still, the results are incredibly promising. Read our story to find out why.

media — pass: No media is selected, and no verified candidate media were supplied, so leaving the media field empty is appropriate.